Mechanism by Which Metal Cofactors Control Substrate Specificity in Pyrophosphatase
Overview
Affiliations
Family I soluble pyrophosphatases (PPases) exhibit appreciable ATPase activity in the presence of a number of transition metal ions, but not the physiological cofactor Mg(2+). The results of the present study reveal a strong correlation between the catalytic efficiency of three family I PPases (from Saccharomyces cerevisiae, Escherichia coli and rat liver) and one family II PPase (from Streptococcus mutans ) in ATP and tripolyphosphate (P(3)) hydrolysis in the presence of Mg(2+), Mn(2+), Zn(2+) and Co(2+) on the one hand, and the phosphate-binding affinity of the enzyme subsite P2 that interacts with the electrophilic terminal phosphate group of ATP on the other. A similar correlation was observed in S. cerevisiae PPase variants with modified P1 and P2 subsites. The effect of the above metal ion cofactors on ATP binding to S. cerevisiae PPase paralleled their effect on phosphate binding, resulting in a low affinity of Mg-PPase to ATP. We conclude that PPase mainly binds ATP and P(3) through the terminal phosphate group that is attacked by water. Moreover, this interaction is critical in creating a reactive geometry at the P2 site with these bulky substrates, which do not otherwise fit the active site perfectly. We propose further that ATP is not hydrolysed by Mg-PPase, since its interaction with the terminal phosphate is not adequately strong for proper positioning of the nucleophile-electrophile pair.
Malykh E, Butov I, Ravcheeva A, Krylov A, Mashko S, Stoynova N Microb Cell Fact. 2018; 17(1):42.
PMID: 29544475 PMC: 5852967. DOI: 10.1186/s12934-018-0890-2.
Structural and Biochemical Characterization of Apicomplexan Inorganic Pyrophosphatases.
Jamwal A, Yogavel M, Abdin M, Jain S, Sharma A Sci Rep. 2017; 7(1):5255.
PMID: 28701714 PMC: 5507929. DOI: 10.1038/s41598-017-05234-y.
Jamwal A, Round A, Bannwarth L, Venien-Bryan C, Belrhali H, Yogavel M J Biol Chem. 2015; 290(51):30498-513.
PMID: 26494625 PMC: 4683271. DOI: 10.1074/jbc.M115.674176.
Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients.
Cunningham J, Rodriguez M, Messa P Clin Kidney J. 2015; 5(Suppl 1):i39-i51.
PMID: 26069820 PMC: 4455820. DOI: 10.1093/ndtplus/sfr166.
An enzymatic platform for the synthesis of isoprenoid precursors.
Rodriguez S, Leyh T PLoS One. 2014; 9(8):e105594.
PMID: 25153179 PMC: 4143292. DOI: 10.1371/journal.pone.0105594.